GLP-1 to ‘I do’: Harvard study finds spike in marriage after women lose weight
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"GLP-1 to ‘I do’: Harvard study finds spike in marriage after women lose weight" is generating significant coverage in the Health category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Economist, The Guardian and NewsNation. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 111d ago.
Quick answers
Why is "GLP-1 to ‘I do’: Harvard study finds spike in marriage after women lose weight" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- How big is America’s “obesity penalty”? The Economist · 116d ago
- Millions of people are losing weight using GLP-1s. How do the drugs affect their love lives? The Guardian · 116d ago
- GLP-1 to ‘I do’: Harvard study finds spike in marriage after women lose weight NewsNation · 116d ago
Topics
Related trends
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
Permitting Bill Would Charge Data Centers Billions for Power
A new Harvard study reveals 400 U.S. hyperscale data centers now consume electricity equal to entire states like Michigan, while a permitting bill proposes charging operators billions for power infrastructure.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.